Pfizer Lung Cancer Treatment Misses Goals

Pfizer Inc.'s treatment for advanced nonsmall cell lung cancer didn't meet goals in two Phase III studies. Both trials evaluated the therapy, called dacomitinib, in populations of previously treated patients.



from WSJ.com: US Business http://ift.tt/LebbCj

via IFTTT